Oncology Learning Network reports that a clinical investigational study led by Winship Cancer Institute, Emory University reports that a combination of carfilzomib and panobinostat was shown to be safe and effective in a heavily pretreated patient with relapsed or refractory multiple myeloma.

This was an open-label, Phase I clinical trial to evaluate the synergy between carfilzomib, a second-generation PI and panobinostat, an HDAC inhibitor. The primary target and goal was to determine the maximum tolerated dose (MTD) of the combination regimen and assess the safety and efficacy of the treatment. Follow the link to review the entire study.

Source: Oncology Learning Network

Pin It on Pinterest